This clinical trial is for men age 18 and older with metastatic castration-resistant prostate cancer (mCRPC), which is prostate cancer that no longer responds to hormone therapy. The cancer spreads (metastasizes) to the bones.
The primary objective of this study is to compare overall survival of subjects treated with docetaxel versus those treated with docetaxel plus radium-223. Radium-223 targets bone metastases and emits low levels of radiation, limiting damage to the surrounding tissues.
Length of time on treatment will vary depending on randomized arm, listed above. Safety follow-up visit will take place 4 weeks after the last dose. End of treatment follow-ups will be every 3 months until the initiation of another therapy, disease progression or death. Subjects will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.